Craig L. Slingluff Jr, MD, director of surgical oncology at the Emily Couric Clinical Cancer Center at the University of Virginia, discusses the use of seviprotimut-L vaccine against melanoma in the B1 Mavis study. Dr. Slingluff emphasizes the importance of developing melanoma vaccines for high-risk patients with no active disease. For a comprehensive approach, seviprotimut-L is comprised of antigens from three melanoma cell lines cultured in vitro. Learn more by clicking here.